Suraksha Diagnostic Limited — PPTs, 05-02-2026: Investor Presentation

**Suraksha Diagnostic: Q3 & 9M FY26 Highlights**

* **Business Performance:** Suraksha Diagnostic posted strong Q3 FY26 results, with consolidated Total Income up 30% YoY to ₹78.31 Cr and PAT rising 21% to ₹7.24 Cr. For 9M FY26, Total Income increased 22% to ₹231.38 Cr and PAT rose 6% to ₹25.24 Cr. This growth is driven by aggressive expansion, including 12 new operational centers.

* **Growth Drivers & Strategy:** The company is "Investing for Scale: Short-term Compression for Long-term Dominance." While new centers cause planned EBITDA compression due to pre-operative costs, mature centers (over 2 years) maintain a robust 37% EBITDA, validating the 'hub and spoke' model. Six more centers are planned for Q4 FY26.

* **Recent Developments:** Suraksha acquired a 63% stake in Fetomat Wellness, integrating fetal medicine expertise. It also launched 'Suraksha Genomics' in July 2025, a new vertical securing a first-mover advantage in Eastern India's high-value genetic testing segment.

* **Outlook:** Management is positive about expansion and Genomics' market reception, expecting current investments to yield significant long-term shareholder value. Future plans involve continued footprint expansion, tech advancements, and strengthening B2B partnerships.